

Survivin 基因的临床研究[J]. 肿瘤研究与临床, 2005, 17(2): 86-88.

[19] TU S P, JIANG X H, LIN M C, *et al.* Suppression of Survivin expression inhibits *in vivo* tumorigenicity and angiogenesis in gastric cancer[J]. *Cancer Res*, 2003, 63(22): 7724-7732.

[20] SUN Y, LIN R, DAI J, *et al.* Suppression of tumor growth using antisense oligonucleotide against Survivin in an orthotopic transplant model of human hepatocellular carcinoma in nude mice[J]. *Oligonucleotides*, 2006, 16(4): 365-374.

[21] 曲贝贝, 左金华. 凋亡抑制基因 Survivin 的研究进展[J]. 中华临床医师杂志, 2014, 8(15): 2842-2846.

[22] SHAN Y, WANG C, YANG L, *et al.* Inhibition of human lung adenocarcinoma growth using Survivin-T34A by low-dose systematic administration[J]. *J Biosci*, 2010, 35(2): 209-216.

[23] ASPE J R, DIAZ OSTERMAN C J, JUTZY J M, *et al.* Enhancement of gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant[J]. *J Extracell Vesicles*, 2014, 3: 23244-23252.

[24] O'CONNOR D S, WALL N R, PORTER A C. A p34(cdc2) survival checkpoint in cancer[J]. *Cancer Cell*, 2002, 2(1): 43-54.

[25] HABIBIE, YOKOYAMA S, ABDELHAMED S, *et al.* Survivin suppression through STAT3/ β -catenin is essential for resveratrol-induced melanoma apoptosis[J]. *Int J Oncol*, 2014, 45(2): 895-901.

[26] ZOU K, TONG E, XU Y, *et al.* Down regulation of mammalian target of rapamycin decreases HIF-1 α and Survivin expression in anoxic lung adenocarcinoma A549 cell to elemene and/or irradiation[J]. *Tumour Biol*, 2014, 35(10): 9735-9741.

[27] 田维军, 赵金伟, 宋晓斌. RNAi 沉默 Survivin 基因对胰腺癌细胞增殖、凋亡和细胞周期的影响[J], 中国老年学杂志, 2010, 30(2): 214-216.

[28] 薛净, 沙卫红, 聂玉强, 等. siRNA 抑制 Survivin 基因及其对人肝癌细胞株 HepG₂ 细胞凋亡的影响[J]. 现代消化及介入诊疗, 2013, 18(4): 205-207.

[29] MEGA S, MIYAMOTO M, LI L, *et al.* Immunohistochemical analysis of nuclear Survivin expression in esophageal squamous cell carcinoma[J]. *Dis Esophagus*, 2006, 19(5): 355-359.

[30] VALLBOHMER D, KUHN E, WARNECKE-EBERZ U, *et al.* Failure in downregulation of intratumoral Survivin expression following neoadjuvant chemoradiation in esophageal cancer[J]. *Pharmacogenomics*, 2008, 9(6): 681-690.

[31] HOFFMANN A C, VALLBOHMER D, GRIMMINGER P, *et al.* Pre-operative Survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma[J]. *Pharmacogenomics*, 2010, 11(3): 341-347.

(本文编辑:李胜利)

(上接第 245 页)

[18] ZHANG Z, ZHU Z, ZHANG B, *et al.* Frequent mutation of rs13281615 and its association with PVT1 expression and cell proliferation in breast cancer[J]. *J Genet Genomics*, 2014, 41(4): 187-195.

[19] CATALANO V, LABIANCA R, BERETTA G D, *et al.* Gastric cancer[J]. *Crit Rev Oncol Hematol*, 2009, 71(2): 127-164.

[20] ZHANG E B, KONG R, YIN D D, *et al.* Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miRNA-99a/miRNA-449a[J]. *Oncotarget*, 2014, 5(8): 2276-2292.

[21] DING J, LI D, GONG M, *et al.* Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer[J]. *Onco Targets Ther*, 2014, 7: 1625-1630.

[22] KONG R, ZHANG E B, YIN D D, *et al.* Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16[J]. *Mol Cancer*, 2015, 14: 82.

[23] EL-SERAG H B, RUDOLPH K L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis[J]. *Gastroenterology*, 2007, 132(7): 2557-2576.

[24] DING C, YANG Z, LV Z, *et al.* Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients[J]. *Oncol Lett*, 2015, 9(2): 955-963.

[25] WANG F, YUAN J H, WANG S B, *et al.* Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2[J]. *Hepatology*, 2014, 60(4): 1278-1290.

[26] JEMAL A, BRAY F, CENTER M M, *et al.* Global cancer statistics[J]. *CA Cancer J Clin*, 2011, 61(2): 69-90.

[27] JONES S, ZHANG X, PARSONS D W, *et al.* Core signaling pathways in human pancreatic cancers revealed by global genomic analyses[J]. *Science*, 2008, 321(5897): 1801-1806.

[28] YOU L, CHANG D, DU H Z, *et al.* Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells[J]. *Biochem Biophys Res Commun*, 2011, 407(1): 1-6.

[29] BAWA P, ZACKARIA S, VERMA M, *et al.* Integrative analysis of normal long intergenic non-coding RNAs in prostate cancer[J]. *PLoS One*, 2015, 10(5): e0122143.

[30] YANG Y R, ZANG S Z, ZHONG C L, *et al.* Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer[J]. *Int J Clin Exp Pathol*, 2014, 7(10): 6929-6935.

[31] TAKAHASHI Y, SAWADA G, KURASHIGE J, *et al.* Amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers[J]. *Br J Cancer*, 2014, 110(1): 164-171.

(本文编辑:王 燕)